Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRXNASDAQ:REPLNASDAQ:VKTXNASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$24.28+2.8%$22.65$14.47▼$26.16$2.96B0.791.11 million shs717,024 shsREPLReplimune Group$9.39+1.3%$10.15$4.92▼$17.00$723.17M1.26871,990 shs529,745 shsVKTXViking Therapeutics$27.94+7.7%$26.27$18.92▼$81.86$3.14B0.844.09 million shs10.75 million shsXENEXenon Pharmaceuticals$38.37+1.4%$34.79$26.74▼$46.00$2.94B1.21445,962 shs944,054 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals+0.77%+7.31%-4.29%+3.46%+58.70%REPLReplimune Group+2.43%+5.70%-10.78%-33.88%+44.39%VKTXViking Therapeutics+3.80%+9.36%+1.13%-24.42%-65.09%XENEXenon Pharmaceuticals+0.58%+9.05%+10.45%-5.40%-6.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPRXCatalyst Pharmaceuticals4.6824 of 5 stars3.62.00.03.93.03.32.5REPLReplimune Group4.1769 of 5 stars3.62.00.04.53.51.70.6VKTXViking Therapeutics4.4784 of 5 stars4.52.00.04.72.33.30.0XENEXenon Pharmaceuticals2.6278 of 5 stars4.51.00.00.03.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.13Buy$32.2932.97% UpsideREPLReplimune Group 3.13Buy$19.43106.91% UpsideVKTXViking Therapeutics 2.93Moderate Buy$87.15211.93% UpsideXENEXenon Pharmaceuticals 3.00Buy$56.7847.97% UpsideCurrent Analyst Ratings BreakdownLatest REPL, CPRX, VKTX, and XENE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$104.004/28/2025VKTXViking TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$95.00 ➝ $75.004/24/2025VKTXViking TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.004/24/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/17/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/17/2025XENEXenon PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $52.004/8/2025VKTXViking TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$30.003/26/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.003/11/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.003/3/2025CPRXCatalyst PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$28.00 ➝ $32.002/28/2025XENEXenon PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$491.73M6.02$2.26 per share10.72$3.30 per share7.36REPLReplimune GroupN/AN/AN/AN/A$6.26 per shareN/AVKTXViking TherapeuticsN/AN/AN/AN/A$3.48 per shareN/AXENEXenon Pharmaceuticals$9.43M311.45N/AN/A$14.18 per share2.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$71.41M$1.3120.5811.403.3131.01%40.79%34.87%5/7/2025 (Estimated)REPLReplimune Group-$215.79M-$3.07N/AN/AN/AN/A-54.84%-42.97%5/15/2025 (Estimated)VKTXViking Therapeutics-$109.96M-$1.15N/AN/AN/AN/A-11.93%-11.57%N/AXENEXenon Pharmaceuticals-$182.39M-$3.02N/AN/AN/AN/A-24.69%-23.68%5/8/2025 (Estimated)Latest REPL, CPRX, VKTX, and XENE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q4 2025REPLReplimune Group-$0.75N/AN/AN/AN/AN/A5/8/2025Q1 2025XENEXenon Pharmaceuticals-$0.94N/AN/AN/A$1.64 millionN/A5/7/2025Q1 2025CPRXCatalyst Pharmaceuticals$0.53N/AN/AN/A$130.86 millionN/A4/23/2025Q1 2025VKTXViking Therapeutics-$0.31-$0.41-$0.10-$0.41N/AN/A2/27/2025Q4 2024XENEXenon Pharmaceuticals-$0.89-$0.84+$0.05-$0.84$0.31 millionN/A2/12/2025Q3 2025REPLReplimune Group-$0.70-$0.79-$0.09-$0.79N/AN/A2/5/2025Q4 2024VKTXViking Therapeutics-$0.27-$0.32-$0.05-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A5.114.92REPLReplimune Group0.1411.4311.43VKTXViking TherapeuticsN/A36.4736.47XENEXenon PharmaceuticalsN/A22.2122.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%REPLReplimune Group92.53%VKTXViking Therapeutics76.03%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%REPLReplimune Group8.80%VKTXViking Therapeutics4.10%XENEXenon Pharmaceuticals5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80121.96 million106.15 millionOptionableREPLReplimune Group21077.02 million70.24 millionOptionableVKTXViking Therapeutics20112.29 million106.20 millionOptionableXENEXenon Pharmaceuticals21076.54 million72.03 millionOptionableREPL, CPRX, VKTX, and XENE HeadlinesRecent News About These CompaniesXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $56.78 Consensus PT from AnalystsApril 29 at 2:11 AM | americanbankingnews.comT. Rowe Price Investment Management Inc. Sells 65,977 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)April 28 at 5:26 AM | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Buy" from AnalystsApril 28 at 2:32 AM | marketbeat.comXTX Topco Ltd Makes New Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)April 27 at 4:03 AM | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Adage Capital Partners GP L.L.C.April 26 at 6:32 AM | marketbeat.comJ. Safra Sarasin Holding AG Invests $697,000 in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)April 26 at 5:43 AM | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Upgraded by StockNews.com to "Hold" RatingApril 26 at 3:11 AM | americanbankingnews.comXenon Pharmaceuticals (NASDAQ:XENE) Upgraded by StockNews.com to Hold RatingApril 26 at 2:13 AM | marketbeat.comEversept Partners LP Acquires New Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)April 24, 2025 | marketbeat.comCapital World Investors Sells 387,000 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)April 24, 2025 | marketbeat.comRock Springs Capital Management LP Has $49.07 Million Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)April 23, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Capital International InvestorsApril 22, 2025 | marketbeat.comMarshall Wace LLP Cuts Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)April 21, 2025 | marketbeat.comThe Goldman Sachs Group Cuts Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $52.00April 20, 2025 | americanbankingnews.comTraders Purchase Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)April 19, 2025 | marketbeat.comLeerink Partnrs Has Positive Outlook of XENE Q1 EarningsApril 18, 2025 | marketbeat.comWalleye Capital LLC Has $8.70 Million Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)April 18, 2025 | marketbeat.comXenon- A Later Stage StoryApril 18, 2025 | seekingalpha.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Affinity Asset Advisors LLCApril 17, 2025 | marketbeat.comStockNews.com Downgrades Xenon Pharmaceuticals (NASDAQ:XENE) to SellApril 17, 2025 | marketbeat.comRussell Investments Group Ltd. Cuts Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)April 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Which Healthcare Stock Is the Best Buy Right Now?By Nathan Reiff | March 31, 2025View Which Healthcare Stock Is the Best Buy Right Now?Viking Therapeutics Stock Pops But Struggles to Hold GainsBy Chris Markoch | April 16, 2025View Viking Therapeutics Stock Pops But Struggles to Hold GainsViking Therapeutics Stock May Struggle After As-Expected ReportBy Chris Markoch | April 25, 2025View Viking Therapeutics Stock May Struggle After As-Expected ReportDelta, Walmart Cut Profit Targets: Could Start Domino EffectBy Thomas Hughes | April 10, 2025View Delta, Walmart Cut Profit Targets: Could Start Domino EffectREPL, CPRX, VKTX, and XENE Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$24.28 +0.65 (+2.75%) Closing price 04:00 PM EasternExtended Trading$24.50 +0.22 (+0.93%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Replimune Group NASDAQ:REPL$9.39 +0.12 (+1.29%) Closing price 04:00 PM EasternExtended Trading$9.40 +0.00 (+0.05%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Viking Therapeutics NASDAQ:VKTX$27.94 +2.00 (+7.71%) Closing price 04:00 PM EasternExtended Trading$28.14 +0.20 (+0.70%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.Xenon Pharmaceuticals NASDAQ:XENE$38.37 +0.53 (+1.40%) Closing price 04:00 PM EasternExtended Trading$38.36 -0.01 (-0.03%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
